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have covered various indications, mostly commonly psychiatric disorders (7 let-
ters), pain (5 letters), and cancer (4 letters). No DDMAC letter pertained to FDAMA
Section 114. CONCLUSIONS: The FDA continues to regulate health economic pro-
motions and express concern about certain inappropriate practices, particularly
unsupported work productivity claims and hidden clinical claims (i.e., about effec-
tiveness or safety) embedded in health economic information. More guidance from
the Agency would help clarify what level of substantiation is required for health
economic promotions.
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OBJECTIVES: To assess the impact of six minimally invasive surgical technologies
on worker absenteeism. METHODS: Using national health insurance claims data
(Thomson-Reuters MarketScan Commercial Database) andmatched data onwork-
place absence and short-term disability (MarketScan Health and Productivity Da-
tabase), we identified 37,495 patients aged 18-64 with employer-sponsored health
insurance who underwent either conventional or minimally invasive surgery dur-
ing 2001-2008 for ischemic heart disease (n18,184), uterine fibroids (n12,795),
prostate cancer (n3,466), peripheral vascular disease (n1,856), aortic aneurysms
(n245), or carotid disease (n949). Our primary endpoint was total days absent
from work, measured as the patient-specific difference between days absent dur-
ing the baseline period (-380 days to -15 days from procedure date) and the periop-
erative and post-operative periods (-14 days to  352 days) to account for individ-
ual-specific illness burden and propensity to use medical care. We studied the
similarly-constructed secondary endpoint of the inflation-adjusted sum of (a) the
dollar value of work absences (valued at $344/day for sick/vacation and $241/day
for short-term disability based on prior studies) and (b) the dollar value of health
plan expenditures for medical care. Propensity scores were constructed using year
of surgery, patient age, gender and Elixhauser comorbidities. RESULTS:Minimally
invasive surgerywas associatedwith fewer unadjusted days of workplace absence,
on average, for prostate cancer (-4.3 days), uterine fibroids (-11.4 days), peripheral
vascular disease (-11.9 days), aortic aneurysms (-20.2 days), and ischemic heart
disease (-26.0 days) (p0.001 for all comparisons). Absences were not significantly
different by surgical approach for carotid disease. The unadjusted sumof the dollar
value of absences and medical care spending was lower for minimally invasive
surgery for uterine fibroids (-$1,512, p0.01), aortic aneurysms (-$18,876, p0.06)
and heart disease (-$33,746, p0.001). Results were comparable after propensity
score adjustment. CONCLUSIONS: Minimally invasive procedures frequently re-
duce worker absenteeism by substantial amounts.
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OBJECTIVES: Assessment of lost productivity through health-related productivity
instruments (HRPIs) is useful for pharmacoeconomic research. The aim of this
study was to conduct a systematic review and critique of HRPIs. METHODS:
Through a comprehensive search in the PubMed database using the keywords
“health-related productivity,” “absenteeism,” and “presenteeism,” the following
generic, validatedHRPIswere found: American Productivity Audit andWorkHealth
Interview (APA&WHI), Endicott Work Productivity Scale (EWPS), Health and Labor
Questionnaire (HLQ), Health and Work Performance Questionnaire (HPQ), Health
and Work Questionnaire (HWQ), Health-Related Productivity Questionnaire-Diary
(HRPQ-D), Stanford Presenteeism Scale (SPS), Work Limitations Questionnaire
(WLQ), Work Productivity and Activity Impairment (WPAI), Work Productivity
Short Inventory (WPSI), and Worker Productivity Index (WPI). All HRPIs were
graded on five major and three minor assessment criteria. Major criteria included
(1) lost productivity could be attributed to a specific health-problem; (2) presentee-
ism was measured; (3) absenteeism was measured; (4) lost productivity was ex-
pressed in hours lost; and (5) productivity could be measured for both those in and
out of the labor force. Minor criteria included (1) how perceived impairment was
measured; (2) the minimum recall period required; and (3) whether population
norms existed or could be obtained. RESULTS: All of the HRPIs except HRPQ-D
failed to provide information on at least one major criterion. The SPS, WLQ, WPAI
and WPSI lacked information on 1 major criterion, APA&WHI, HLQ and HPQ on 2
major criteria, EWPS on 3major criteria and HWQ on 4major criteria. The HRPQ-D,
SPS, WLQ, WPAI and WPSI satisfied all or at least 1 major criterion but lacked 1-3
minor criteria. The common major criterion frequently lacking among the SPS,
WLQ, WPAI andWPSI was either household-related productivity loss or valuation.
CONCLUSIONS: Current HRPIs lack comprehensive estimation of lost productivity.
There is an opportunity to develop stronger survey instruments.
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OBJECTIVES: There are no studies in the United States examining the trends in
mortality rates, years of potential life lost (YPLL), and value of productivity losses
due to breast cancer (BC) amongwomen aged 20-49 years.We examined the trends
in BCmortality rates by geographic region, estimated YPLL and value of productiv-
ity losses by race/ethnicity. METHODS: National mortality data from 1970-2008
were used to calculate age-adjusted mortality rates and rate ratios (RRs). Joinpoint
regression analysis was used to assess changes in trends over time. The YPLL were
calculated to quantify the burden of prematuremortality. The value of lost lifetime
productivity earnings of young women who died of BC in 2008 were used to quan-
tify the expected future value of lost productivity due to premature mortality.
RESULTS: From 1970 through 2008 the age-adjusted mortality rate from BC among
white youngwomenwas 11.45/100,000 and 17.97/100,000 among blacks. Compared
with whites, blacks had substantial higher age-adjusted breast cancer mortality
rates. BC mortality rates vary by geographic region. The decline in BC mortality
rates among blacks has been small (-0.68% per year) compared with whites (-2.02%
per year). During the same period, the total number of deaths associatedwith BC in
young women was 225,866, which accounted for an estimated 7.98 million YPLL.
The estimated total productivity losses attributed to BC in young women who died
in 2008 was $5.49 billion. On average, a young woman who died from BC in 2008
would lose $1.10 million in forgone lifetime earnings. CONCLUSIONS: Although
blacks have substantially higher age-adjusted BC mortality rates, there has been
very little overall change in death rates over time compared to other races. Our
results may implicate the need for focused attention to racial disparities in BC
diagnosis, treatment, and survivorship efforts among specific populations.
PODIUM SESSION III:
RESEARCH ON MEDICAL OUTCOMES QUESTIONNAIRES
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OBJECTIVES: To develop a revised version of the Medical Outcomes Study Sleep
Scale (MOS-Sleep-R), and to evaluate its psychometric properties within a repre-
sentative sample of US adults. METHODS: The MOS-Sleep, developed in the late
1980s, is a 12-item patient-reported instrument measuring sleep outcomes over
the previous 4 weeks, yielding six domain scores – Disturbance, Adequacy, Som-
nolence, Snoring, Awakening to due to shortness of breath/headache, andQuantity
– and two global Sleep Problem Indices (SPI). The MOS-Sleep-R implemented the
following changes: the response option “a good bit of the time” was removed; a
1-week recall period formwas introduced; and 0-100 scores were replaced by stan-
dardized T-scores (mean50, standard deviation10 in the US general population)
with higher scores reflecting better sleep outcomes. Standardization was based on
data from a 2009 US internet-based general population survey. The psychometric
properties of both 1-week and 4-week recall forms of the MOS-Sleep-R were exam-
ined within this development sample. RESULTS: The 1-week and 4-week recall
forms of the MOS-Sleep-R were completed by 2045 and 2033 respondents, respec-
tively. The psychometric properties of the 1-week and 4-week forms were similar.
Patterns of inter-item and item-scale correlations support the scaling assumptions
of the instrument. All multi-item domains, global index scores, and the total scales
showed adequate internal consistency reliability (all Cronbach’s  0.75). Patterns
of correlations between MOS-Sleep-R scores with criterion measures of quality of
life, psychological state, and work and health outcomes indicated adequate con-
vergent validity. Differences in mean scores across groups that differed on the
criterion outcomes supported the instrument’s discriminant validity.
CONCLUSIONS: The MOS-Sleep-R introduces a number of improvements, includ-
ing simplified response sets, the introduction of a 1-week recall form, and norm-
based scoring that enhances interpretability of scores. Both the 1-week and 4-week
recall period forms of the MOS-Sleep-R demonstrated good reliability and validity.
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OBJECTIVES: The ENSEMBLE MDS is a battery of phenotypic patient-reported in-
struments administered at baseline in clinical studies. The component measures
assess potential predictors (Self-Reported Health Status (SRH), Total Illness Burden
Index (TIBI), Patient Health Questionnaire-4, Depression Diagnosis, Perceived
Stress Scale) or effect modifying factors of clinical outcomes and/or treatment
response (MacArthur Perceived Status Ladder, MacArthur Income, Barratt Simpli-
fied Measure of Social Status, Perceived Social Support Scale (SS-5). This report
furthers the initial validation conducted in the United States by evaluating the
reproducibility and construct validity outside the United States. METHODS: The
ENSEMBLE MDS and other assessments (MOS SF-36, EQ-5D, Life Orientation Test-
Revised (LOT-R), items on illness/bed days and doctor visits) were administered to
a sample of adults with depression, type 2 diabetes, or rheumatoid arthritis in
Germany (n61), Spain (n61) and Singapore (n56, Simplified Chinese). Partici-
pants completed the battery on paper and returned one-week later to complete a
retest. Test-retest reproducibility was assessed using the intraclass correlation
coefficient (ICC); convergent validity by Pearson correlations between MDS instru-
ments and components of the SF-36 and EQ-5D, with hypothesized relationships
significant at r0.30; and known-groups tested using tertiles of the LOT-R, doctor
visits and illness days. RESULTS: The mean age of the participants was 5513
years, 63% were female, 66% were married/living with partner. Between 85% and
100% completed MDS instruments at the retest (mean 6.70.6 days). The ICCs for
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